



## Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference

January 7, 2022

WALTHAM, Mass., Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 08:15 a.m. ET.

A live webcast of the presentation can be accessed from the Investor section of the Company's website at [www.syndax.com](http://www.syndax.com), where a replay of the event will also be available for a limited time.

### About Syndax Pharmaceuticals, Inc.


Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit [www.syndax.com](http://www.syndax.com) or follow the Company on [Twitter](#) and [LinkedIn](#).

### Syndax Contacts

Investor Contact  
Melissa Forst  
Argot Partners  
[melissa@argotpartners.com](mailto:melissa@argotpartners.com)  
Tel 212.600.1902

Media Contact  
Benjamin Kolinski  
[benjamin.kolinski@qcihealth.com](mailto:benjamin.kolinski@qcihealth.com)  
Tel 862.368.4464

SNDX-G

 View original content: <https://www.prnewswire.com/news-releases/syndax-announces-presentation-at-40th-annual-jp-morgan-healthcare-conference-301456071.html>

SOURCE Syndax Pharmaceuticals, Inc.